Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Spotify Technology (SPOT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Spotify Technology — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $298.83 (market cap $39.89B), while Spotify Technology trades at $481 (market cap $98.65B). The key difference: Spotify Technology is far larger — about 2.5× Alnylam Pharmaceuticals, Inc.'s market cap, and Spotify Technology is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | SPOT | |
|---|---|---|
Market Cap | $39.89B | $98.65B |
Sector | Health | Media |
52-Week High | $491.22 | $738.53 |
52-Week Low | $278.09 | $412.75 |
Enterprise Value | $38.15B | $89.23B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Spotify (SPOT) trades at $479.77, down 1.26% amid broader market strength, but maintains strong fundamental momentum with consistent earnings beats and accelerating revenue growth. The stock shows bullish technical positioning above key support levels, with analyst consensus strongly favoring buy ratings and a $617 price target representing 29% upside potential. Recent quarterly results have exceeded expectations, with Q1 2026 EPS of $4.04 beating estimates by 18%, demonstrating operational efficiency improvements.
The outlook remains positive with projected revenue growth to $17.5B in 2026 and expanding profit margins. Key risks include competitive pressure from streaming rivals and market volatility, but strong institutional support and consistent execution provide a solid foundation for continued appreciation toward analyst targets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Spotify Technology
Spotify Technology S.A. provides music streaming services. The Company offers commercial-free music and ad-supported services to subscribers. Spotify Technology serves clients worldwide.
Read more on SPOT →
